Replies to post #43 on Zimmer Biomet Holdings Inc (ZBH)

[DewDiligence]

ZBH -7% because of soft 2022 guidance announced with 4Q21 results:

https://finance.yahoo.com/news/zimmer-biomet-announces-fourth-quarter-113000363.html

The Company is providing the following full-year 2022 financial guidance for RemainCo Zimmer Biomet – this guidance does not include any projected financial results from the businesses that are part of the planned spinoff of ZimVie from the Company. For comparison purposes only, unaudited 2021 net sales for RemainCo Zimmer Biomet are estimated to be $6.827 billion, based on total Company net sales of $7.836 billion less the Dental & Spine product category net sales of $1.009 billion.

Projected Year Ending December 31, 2022

 2022 Reported Revenue Change     (4.0)-0.0% 
 Foreign Currency Exchange Impact (2.0)% 
 Adjusted Operating Profit Margin  26.5-27.5% 
 Adjusted Tax Rate                 16.0-16.5% 
 Adjusted Diluted EPS             $6.40-6.80

The word, “adjusted” in the above table means non-GAAP.

[DewDiligence]

ZIMV 2022 non-GAAP EPS guidance=$2.10-2.30:

https://finance.yahoo.com/news/zimvie-hosts-inaugural-investor-day-141500225.html

[DewDiligence]

This is ZBH’s biggest biz-dev transaction since the merger of Zimmer and Biomet in 2015.

[DewDiligence]

ZBH is now trading ex-spinoff of ZIMV.

[DewDiligence]

ZBH divested its_equity_stake_in ZIMV spin-off in cashless swap of equity for debt:

https://www.sec.gov/Archives/edgar/data/1136869/000106299323002100/xslF345X03/form4.xml